Operating within the United States, eXoZymes, Inc. is a pioneering synthetic biochemical enterprise. The company's primary innovation is SimplePath, a sophisticated platform engineered to synthesize a diverse spectrum of chemicals. This output encompasses essential pharmaceuticals, alternative fuels, advanced materials, food additives, and entirely new molecular entities. Integral to its design, the SimplePath platform incorporates distinct modules, each housing one or more enzymes that work synergistically to facilitate specific biocatalytic transformations. The firm was established in 2014 and maintains its corporate headquarters in Monrovia, California.

Employees - 31, CEO - Michael Heltzen, Sector - Healthcare, Country - US, Market Cap -

Altman ZScore(max is 10): -1.2, Piotroski Score(max is 10): 1, Working Capital: $507585, Total Assets: $4018841, Retained Earnings: $-23474939, EBIT: -10135990, Total Liabilities: $2490741, Revenue: $0

AryaFin Target Price - $0.21 - Current Price $ - Analyst Target Price $